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Introductory Paragraph 29 
Next generation sequencing (NGS) of circulating tumour DNA (ctDNA) 30 
supports blood-based genomic profiling but is not yet routinely implemented in 31 
the setting of a phase I trials clinic. TARGET is a molecular profiling 32 
programme with the primary aim to match patients with a broad range of 33 
advanced cancers to early phase clinical trials based on analysis of both 34 
somatic mutations and copy number alterations (CNA) across a 641 cancer-35 
associated gene panel in a single ctDNA assay. For the first 100 TARGET 36 
patients, ctDNA data showed good concordance with matched tumour and 37 
results were turned round within a clinically acceptable timeframe for 38 
Molecular Tumour Board (MTB) review. When applying a 2.5% Variant Allele 39 
Frequency (VAF) threshold, actionable mutations were identified in 41/100 40 
patients and 11 of these patients received a matched therapy. These data 41 
support the application of ctDNA in this early phase trial setting where broad 42 
genomic profiling of contemporaneous tumour material enhances patient 43 
stratification to novel therapies and provides a practical template for bringing 44 
routinely applied blood-based analyses to the clinic. 45 
  46 
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Results and Discussion 47 
The selection of patients to early phase clinical trials and clinical outcomes 48 
can be enhanced by molecular stratification (1-6) and most precision medicine 49 
strategies to date are based on DNA sequencing of archival or fresh tumour 50 
biopsies (7-9). However, genomic profiling of archival specimens can be 51 
limited by sample age, quality, low tumour content and tumour heterogeneity. 52 
Also, archival samples by their very nature, do not take into account on-going 53 
tumour evolution, particularly if patients have received therapies which may 54 
confer acquired resistance. Acquisition of fresh tissue is often challenging and 55 
not without patient risk, yet there is increasing demand for tumour material in 56 
the context of clinical trials and molecular profiling. ctDNA is extractable from 57 
a peripheral blood sample and provides a contemporaneous profile of the 58 
tumour genomic landscape. NGS technology has evolved for reliable 59 
sequencing of ctDNA (10,11), but clinical validation is needed to drive forward 60 
routine use of ctDNA in the clinic (12). The TARGET (Tumour 61 
chARacterisation to Guide Experimental Targeted therapy) study was 62 
designed to determine the feasibility of using ctDNA, relative to tissue-based 63 
testing to identify clinically actionable mutations in early phase clinical trial 64 
patients with a range of advanced stage cancers (Figure 1a). Our study was 65 
divided into Part A (100 patients) to establish an analytical workflow and 66 
assess feasibility of data turnaround in a timeframe of 2-4 weeks to support 67 
clinical decision-making, and Part B (450 patients) to test clinical utility 68 
following selection of patients in real-time to molecularly matched trials based 69 
on their ctDNA and/or tumour genomic profile. Here we present data from Part 70 
A of the TARGET trial demonstrating the ‘real world’ feasibility for routine 71 
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implementation of ctDNA profiling to increase the chance of matching patients 72 
with advanced cancers to a Phase I trial of an appropriate targeted therapy.  73 
The first 20 patients’ blood samples were used to optimise the ctDNA 74 
workflow with automated ctDNA purification demonstrating comparable yields 75 
to manual isolations (Extend Data Figure 1a). Hybridization and enrichment of 76 
a 2.1Mb Agilent SureSelect panel targeting 641 genes recurrently mutated in 77 
cancers (Supplementary Table ST1) to the ctDNA library and germline control 78 
for each patient resulted in an average 1322-fold enrichment (range 359-79 
5804) of targeted genes (Extend Data Figure 1b). Sensitivity and 80 
reproducibility of the NGS assay was tested on a reference panel of five 81 
samples with highly characterized genotypes from the European Molecular 82 
Genetics Quality Network (EMQN).  All 14 reference mutations in the five 83 
EMQN samples were detected with 100% specificity and sensitivity and >90% 84 
correlation of expected allele frequency across all mutations detected (Extend 85 
Data Figure 1c). 86 
Having demonstrated the reliability of the ctDNA workflow, we expanded the 87 
cohort to 100 patients referred to the Experimental Cancer Medicine Team 88 
(ECMT) at The Christie NHS Foundation Trust for consideration of early 89 
phase trials. The patient cohort consisted of 22 different tumour types, with a 90 
median age of 56 years and patients had received a median of two prior lines 91 
of therapy (Extend Data Figure 2, Supplementary Table ST2). ctDNA NGS 92 
data was generated successfully for 99% of patients, compared to tumour 93 
tissue DNA analysis in 95% (Figure 1b). The average de-duplicated read 94 
depth across all ctDNA samples was 699 (range 108-1760) (Supplementary 95 
Table ST3). In this cohort of patients, 67% of tumour biopsies were >1 year 96 
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old and 36% >3 years old (range 0-5635 days pre-blood collection) (Figure 97 
1b) highlighting the benefit of ctDNA sampling.  98 
Critical to any molecular profiling program is turnaround of results within a 99 
meaningful timeframe to facilitate clinical decision-making for an individual 100 
patient and to minimise the risk of dropout from clinical trial participation due 101 
to declining health. Our data show comparable report times for FFPE tumour 102 
tissue analysis and ctDNA; with a mean report time from blood draw of 33 103 
calendar days (range 20-80) for patients 21-100, comparable to a mean 104 
tumour DNA report time of 30 calendar days (range 17-140) from date of 105 
consent to receipt of result (Figure 1c). 106 
All tumour samples were analysed in a National Health Service (NHS), 107 
ISO15189 accredited clinical laboratory, initially using a 19-gene MassArray 108 
assay (Sequenom OncoCarta™ v1.0; 57% patients) and more recently a 24-109 
gene GeneRead PCR amplicon assay (Qiagen Clinically Relevant Tumour 110 
Targeted Panel V2; 43% patients), which represent cancer panel assays 111 
clinically accredited in the UK NHS at the time of the study. A total of 69 non-112 
synonymous mutations were identified in tumours across 54 patients, with no 113 
mutations reported for the remainder. Analysis of the corresponding mutations 114 
in the ctDNA NGS data revealed good concordance, with 54/69 mutations 115 
(78.6%) also detected (Figure 1d, Extend Data Figure 3). This level of 116 
concordance, even accounting for differences between gene panels and 117 
levels of sensitivity between the tumour and ctDNA assays compares 118 
favourably with other recently described studies (10,13,14). The ctDNA assay 119 
was also compared to the FoundationOne® panel in a subset of 39 patients 120 
where the matched tumour also underwent Foundation Medicine testing 121 
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(Supplementary Table ST4). This enabled analysis across a broader panel of 122 
230 genes present in both the 641-gene and FoundationOne® panels. In this 123 
patient subset 74 mutations were reported in the ctDNA, of which 52 were 124 
also reported in the tumour (70% concordance). A larger number of mutations 125 
were reported in the FoundationOne® tumour analysis for these patients, 126 
which most likely reflects a combination of a high tumour fraction in the input 127 
DNA and the ability to identify mutations belonging to minor tumour subclones 128 
that could not be picked up in ctDNA (Extend Data Figure 4).  129 
For reporting mutations to the MTB, we applied a 2.5% VAF threshold to 130 
ensure reliability and robustness. Though more sensitive approaches are 131 
available (13), our rationale for TARGET was to evaluate whether a 2.5% VAF 132 
cut-off was suitable for clinical application and treatment decision making for 133 
phase I patients with advanced disease often having exhausted other 134 
treatment options. It has been shown that ctDNA yield is linked to tumour cell 135 
proliferation and death rates (15, 16) and therefore all ctDNA-based assays 136 
may have some bias towards higher tumour burden that should be taken into 137 
consideration when interpreting associated results. With this in mind, we 138 
asked whether the higher VAF threshold used here would result in bias 139 
towards patients with higher ctDNA yield or higher tumour burden. We did not 140 
find a significant correlation between VAF and cfDNA yield (Extend Data 141 
Figure 5a and 5b), which may be due to our cohort being phase I clinical trial 142 
patients, who will tend to have a large tumour burden and ctDNA yield. 143 
However, a significant correlation was observed between average VAF and 144 
number of metastatic sites (p = 0.0118), which was used here as a surrogate 145 
of tumour burden (Extend Data Figure 5c and 5d). Whilst our 2.5% VAF 146 
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threshold might result in ‘false negatives’ and inherently bias towards patients 147 
with higher disease burden it will reduce ‘false positives’ and the assay 148 
facilitates broad panel testing for a diverse range of alterations required in the 149 
phase I trial setting, compared with smaller panel or single gene assays 150 
where the sensitivity may be higher. 151 
Using the 2.5% VAF threshold 70/94 patients with both tumour and ctDNA 152 
analysed showed concordance of reported mutations (74.5%)(Figure 1e). 153 
Discordance occurred in 24 patient samples: 20/24 had tumour mutations 154 
undetected in ctDNA (9 of these mutations were detectable in ctDNA, but 155 
below the 2.5% VAF threshold) and 4/24 had mutations in ctDNA, but not 156 
corresponding tumour. No correlation between tumour biopsy age and 157 
mutation discordance with ctDNA was evident (Extend Data Figure 6). Where 158 
discordance was seen, this could often be ascribed to either a biological or 159 
clinical consequence: for example, TAR-039, a colorectal cancer patient 160 
exhibited a KRAS c.34G>T p.(Gly12Cys) mutation in their ctDNA (VAF 3.4%), 161 
which was not detected in the archival tumour specimen collected 26 months 162 
previously. This is likely linked to the administration of anti-EGFR therapy 163 
(panitumumab) in the intervening period to which KRAS mutation is a well-164 
described mechanism of resistance (17).  165 
A 641-gene panel was designed for application in the early phase ‘all cancer 166 
types’ trial setting because of its potential to provide a broader coverage of 167 
alterations/co-mutations, mechanisms of resistance and facilitate the selection 168 
of novel targeted agents. The ctDNA assay provided a broad view of the 169 
mutational landscape across the various cancer types, with ≥1 mutation 170 
detected in 70% of patients (Extend Data Figure 7, Supplementary Table 171 
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ST5). Clear differences were seen in the number and allele frequencies of 172 
mutations across tumour types (Figure 1f), though patient numbers were too 173 
small to assign significance. We propose that this ctDNA assay will be most 174 
useful for certain patient populations/histological sub-types since in our study 175 
no mutations were detected in certain tumour types (e.g. adrenal cancer), 176 
whereas in others, for example breast cancer, SCLC and CUP >80% patients 177 
had detectable ctDNA mutations. These data are based on limited patient 178 
numbers and could be confounded by differences in tumour volume and as 179 
such require validation in larger patient cohorts.  180 
Another advantage of the broad panel targeted enrichment approach is that it 181 
enables evaluation of CNA, as well as mutation profiling within the same 182 
assay. The ability to accurately call CNA is important as many clinically 183 
actionable alterations in cancer are structural alterations (18) as evidenced by 184 
the GENIE cohort (19) of 13,641 patients where structural variants accounted 185 
for 43% of 17,069 actionable mutations (personal communication, Dr Philip 186 
Beer). ctDNA CNA was compared to tissue-based CNA in a subset of 8 187 
patients who had standard low-pass, whole genome sequencing (WGS) of 188 
their ctDNA (20), and in 23 patients where the matched tumour had CNA 189 
reported following FoundationOne® analysis (Figure 2a, Supplementary Table 190 
ST4). High concordance was seen between genome-wide CNA analysis of 191 
the 641-gene pull-down ctDNA and low-pass WGS profiles (Extend Data 192 
Figure 8). Concordant gene-level alterations were detected in 11/23 (48%) 193 
patients with both tumour FoundationOne® and ctDNA analysis available 194 
(Extend Data Figure 9, Supplementary Table ST6). As previously reported 195 
(21, 22) accurate CNA calling from ctDNA requires a higher fraction of ctDNA 196 
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in the sample and when we applied an average VAF ≥5% threshold (15/23 197 
patients) for CNA analysis, concordance with tumour increased to 11/15 198 
(73%, Extend Data Figure 9). 199 
An important aim for Part A of TARGET was to establish a routine MTB for the 200 
formal reporting and discussion of tumour and ctDNA mutational profiles of 201 
the 100 Part A patients. A challenge identified at the MTB was efficient and 202 
effective integration of clinical and genomic data. This prompted the 203 
development of eTARGET, an in-house digital solution integrating a single 204 
overview of patients’ clinical and genomic characteristics.  eTARGET includes 205 
a storage account for data upload, a database for storing and integrating data 206 
and a web-application for data visualisation (Extend Data Figure 207 
10). eTARGET enables the MTB to review summary patient data via a single 208 
portal (and remotely if required), capture meeting outcomes in real-time and 209 
upload information to electronic patient records.  210 
A potential reason why large molecular screening programs have traditionally 211 
allocated only 10-15% of patients to studies may be in the interpretation of 212 
variants of unknown significance (VUS)(7,8,9). It is challenging for any MTB to 213 
have knowledge of all possible variants and databases are in development for 214 
pooling relevance of VUS (23,24). We addressed this issue by accessing 215 
software packages to aid interpretation of the relevance of specific variants 216 
and identify appropriate trials in different regions of the UK or in Europe. The 217 
Qiagen Clinical Interface (QCI) software package was considered valuable in 218 
differentiating actionable mutations (and recommended matched therapies) 219 
from those of unlikely clinical relevance and provided tiering following 220 
ACMG/AMP/CAP guidelines.  221 
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Following MTB review, 41 of the first 100 TARGET patients had an alteration 222 
considered to be actionable of whom 11 received a matched therapy, 17 223 
received a non-matched therapy (largely due to trial availability at site) and 13 224 
either had no trial available, did not meet study specific eligibility, deteriorated 225 
clinically or went on to a chemotherapy option (Figures 2b and 2c). For the 11 226 
patients that received a matched therapy, partial response (PR) was achieved 227 
in 4/11 and stable disease (SD) (minimum of 3 months) was observed in 7/11 228 
patients. Median duration on therapy was 6 months (range 1.5-20 months) 229 
(Figure 2d). Of the 17 patients that received non-matched therapy 0/17 230 
showed response to therapy and 4/17 achieved SD (Figure 2c). An example 231 
of a patient matched to a clinical trial based on ctDNA analysis following 232 
discussion at the MTB is patient TAR-012; a 57-year-old female with lung 233 
adenocarcinoma who progressed through first-line cisplatin-pemetrexed 234 
chemotherapy. ctDNA profiling revealed an NRAS c.181C>A  p.(Gln61Lys) 235 
mutation, also confirmed in her archival tumour. The patient was matched to a 236 
Phase I trial of a first-in-human MEK inhibitor and demonstrated PR with 60% 237 
reduction in marker lesions (RECIST 1.1) and symptomatic benefit (Figure 238 
2e). Her disease remained controlled for 12 months. This is the first NRAS 239 
positive NSCLC patient reported, as far as we aware, to demonstrate 240 
radiological and clinical response to single agent MEK inhibition in keeping 241 
with pre-clinical data that strongly support this approach (25).  242 
The overall intent of TARGET was to develop a robust workflow supporting 243 
clinical decision-making that can be delivered on a routine basis, with data 244 
turnaround time compatible with clinical practice, at an affordable cost 245 
(approximately £1600 per patient) that leads to benefit in a proportion of 246 
 - 11 - 
phase I trial patients. With the feasibility of the workflow demonstrated in Part 247 
A, Part B of TARGET was initiated in Feb 2017 with the intention to recruit a 248 
further 450 patients over 3 years. In Part B, our primary aim is to improve 249 
matching of patients to clinical trials according to the molecular profile of their 250 
cancer and data will be prospectively collected for overall response rates and 251 
clinical outcomes for all patients to compare between matched and non-252 
matched therapies. The turnaround time of results will also be shortened to 253 
15-20 calendar days. 254 
Our experience on the TARGET study encourages routine implementation of 255 
ctDNA testing as an adjunct to tumour testing. We suggest that with increased 256 
experience and on-going development of more sensitive ctDNA assays, such 257 
as incorporation of Unique Molecular Identifiers or other emergent 258 
methodologies, it may be possible to assign certain cancer patients to blood 259 
based testing. Tumour analysis would be applied only in cases with lower 260 
tumour burden or low ctDNA yields where blood analysis maybe 261 
unsuccessful, thereby reducing invasive procedures for patients and the 262 
associated healthcare system costs.  263 
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Figure Legends 464 
Figure 1.  Overview of analysis of the first 100 patients recruited to the 465 
TARGET study. a) Outline of the approaches used for ctDNA and tumour 466 
analysis in the TARGET study. b) Average de-duplicated read depth for first 467 
100 TARGET patients. A threshold of ≥100 average de-duplicated reads was 468 
set as a QC for reporting of data to the MTB (blue line). Reporting rate for 469 
tumour is indicated below the graph with failed samples indicated in red 470 
boxes, successful samples green boxes. The age of tumour biopsies at the 471 
time of analysis is indicated below the graph with biopsies <1 year old, 1 to 3 472 
years and >3 years old indicated. c) Reporting times from the time of blood 473 
collection to generation of variant report for submission to the MTB in 474 
calendar days is shown for patients TAR-081 to TAR-100. The average time 475 
taken for patients 21-100 for ctDNA (mean=33 days, SD=+/-9 days SD, n=80) 476 
and tumour (mean=30 days, SD=+/-15 days, n=75) is indicated at the bottom 477 
of the graph. Calendar days taken to complete ctDNA isolation (red box), 478 
NGS generation (grey box) and bioinformatic analysis (blue box) are 479 
indicated. d) Bar graph showing concordance of mutations detected across 19 480 
and 24-gene clinical panels in tumour and ctDNA for first 100 TARGET 481 
patients. Graph shows number of high confidence concordant mutations (dark 482 
green), mutations found below the 2.5% VAF Level of Detection (light green) 483 
and discordant mutations (red). e) Bar graph showing concordance of 94 484 
TARGET patients for which combined tumour and ctDNA data was available. 485 
Concordant patients are indicated in blue (dark blue no mutations detected, 486 
light blue concordant mutations detected) and discordant patients in grey 487 
(mutation present only in tumour: light grey, mutation present only in ctDNA: 488 
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dark grey). f) Table showing number and VAF of mutations detected in 489 
extended 641-gene panel in ctDNA from first 100 TARGET patients according 490 
to disease type. 491 
 492 
Figure 2.  Analysis of CNA, actionable mutations and clinical response 493 
for the first 100 TARGET patients. a) Heat map showing CNA derived from 494 
ctDNA of 23 patients with corresponding Foundation Medicine CNA data. 495 
Regions of gain (red) and loss (blue) are indicated with chromosome number 496 
shown above. The average VAF and tumour type for each patient is indicated 497 
on the right of the heat map. Specific genes called amplified (red) or deleted 498 
(blue) within the tumour and ctDNA from three exemplar patients is shown on 499 
the far right. b) Schematic showing number of actionable mutations identified 500 
in the first 100 TARGET patients and efficiency of recruiting to a matched 501 
therapy (11%) using tumour and ctDNA mutation profiling. c) Consort diagram 502 
to show treatment decisions for the 41 patients with actionable alterations. 503 
The overall response rate (ORR) was 4/11 for patients on a matched therapy 504 
compared with 0/17 for those patients on an unmatched therapy. Stable 505 
disease rates were also higher in the matched trial cohort. d) Table showing 506 
details of the 11 patients recruited to matched therapies from TARGET Part A. 507 
All patients had partial response or stable disease with a median duration of 508 
response of 6 months. Actionability shown according to ACMG/AMP/CAP 509 
guidelines. ND = mutation not detected in ctDNA of patient. PR = partial 510 
response, SD = stable disease. e) Summary of ctDNA analysis for patient 511 
TAR-012 with non-synonymous mutation identified in ctDNA shown in the first 512 
box with mutations overlapping with the clinical tumour panel highlighted in 513 
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purple and clinical actionability according to ACMG/AMP/CAP guidelines 514 
indicated. CNA profile and genes amplified (red) or deleted (blue) are shown 515 
below mutation results. CT scans of patient showing clinical response pre and 516 
post 2-months of targeted therapy is also shown with yellow arrows identifying 517 
sites of disease.  518 
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Online Methods 519 
 520 
Ethics approval 521 
This study was undertaken in accordance with the ethical principles 522 
originating from the Declaration of Helsinki and in accordance with Good 523 
Clinical Practice. The study was approved by the North-West (Preston) 524 
National Research Ethics Service in Feb 2015, reference 15/NW/0078 and 525 
was registered on the NIHR Central Portfolio Management System, reference 526 
CPMS ID 39172. All patients were recruited within the Experimental Cancer 527 
Medicine Team at The Christie NHS Foundation Trust and provided fully 528 
informed written consent for provision of tumour and blood samples for 529 
genetic analyses. The University of Michigan Flexible Default Model was used 530 
for consent (26) that considers cancer related genetics from hereditary-related 531 
alterations. Whilst the study is focused predominantly on somatic alterations, 532 
the default is to inform patients of all genomic alterations, including those that 533 
could impact on family or risk of other diseases unless patients opt out. 534 
Specific optional consent was acquired for use of samples for cell culture or 535 
animal experiments.  536 
 537 
Clinical workflow  538 
TARGET is a two part study divided into Part A, feasibility of the workflow, 539 
ctDNA and tumour sequencing validation, formal reporting and setting up the 540 
MTB; and Part B, expansion to match patients to clinical trials and therapies in 541 
real-time (Figure 1a). Here we report results from Part A (N=100). The study 542 
recruited patients referred to the Experimental Cancer Medicine Team at The 543 
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Christie NHS Foundation Trust for consideration of early phase trials. Most 544 
patients had exhausted standard-of-care treatment options. Patients had to be 545 
ECOG PS0-1 and suitable clinical trial candidates, thus no or controlled co-546 
morbidities and acceptable biochemical and haematology parameters in 547 
keeping with phase I trial inclusion criteria. The study excluded patients who 548 
were declining rapidly, poor performance status (PS) or high-risk blood 549 
sample donors. Following fully informed written consent blood and tissue 550 
samples were acquired and processed as detailed. Once results were 551 
available, data were discussed within a monthly MTB consisting of clinicians, 552 
clinical and translational scientists, bioinformaticians, basic scientists and 553 
biologists to interpret significance of variants and recommended trials or 554 
therapies. Software packages were also used to assist in determination of 555 
pathogenicity of VUS and a bespoke software package, eTARGET was 556 
developed as a digital solution to integrating clinical and genomic data digitally 557 
to facilitate MTB discussion, meeting outcome capture and to serve as a 558 
searchable database for data interrogation. The allocation of patients to 559 
treatment did not follow a specific algorithm as the process was dynamic and 560 
the treatment decision reached by the MTB was based on the specific 561 
mutations identified, VAF, associated pathogenicity (based on QCI tiering and 562 
evaluation), context in presence of co-mutations, patient treatment history, co-563 
morbidities, fitness and available clinical trial options.  564 
 565 
Blood Processing and Circulating Cell-Free DNA Extraction 566 
Blood was collected in 10 ml BD Vacutainer K2E (EDTA) tubes (Becton-567 
Dickinson) and 4 x 10 ml Streck Cell-Free DNA BCT blood collection tubes 568 
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(Streck) during routine phlebotomy. Germline DNA (gDNA) was isolated from 569 
EDTA whole blood using the QIAmp Blood Mini Kit (Qiagen, Hilden, 570 
Germany) as per manufacturer's instructions, and sheared to 200-300 bp on 571 
the Bioruptor Pico (Diagenode). Double-spun plasma was isolated from all 572 
Streck ctDNA BCT blood samples within 96 hours of blood collection and 573 
stored at −80 °C prior to ctDNA analysis. ctDNA was isolated using the 574 
QIAmp Circulating Nucleic Acid Kit (Qiagen) according to the manufacturer's 575 
instructions and/or the QIAsymphony with the Circulating DNA Kit (Qiagen). 576 
ctDNA and sheared gDNA yields were quantified using the TaqMan RNase P 577 
Detection Reagents Kit (Life Technologies). 578 
 579 
Targeted sequencing of ctDNA and analysis 580 
Sequencing libraries were generated from 0.5 to 25 ng ctDNA, or 25 ng 581 
sheared germline DNA in Accel-NGS 2S DNA Library Kits for the Illumina 582 
Platform (Swift Biosciences, Ann Arbor, MI) by the manufacturer's instructions 583 
with the following modifications. Library amplification and indexing was carried 584 
out with KAPA HiFi HotStart PCR Kits (Kapa Biosystems, Wilmington, MA) 585 
and NEBNext Index Primers for Illumina (New England Biolabs). 1 μg of each 586 
indexed library were pooled (up to 6 μg) as input for custom capture (641 587 
gene panel) on SureSelectXT Reagent Kits (Agilent, Santa Clara, CA) by the 588 
manufacturer's instructions. Captured libraries were amplified using KAPA 589 
HiFi HotStart PCR Kits and quantified using the KAPA library quantification 590 
qPCR kit (Roche).  Libraries were paired-end sequenced on an Illumina 591 
NextSeq 500, 2x 150bp High Output V2 kit (Illumina).  592 
 593 
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NGS Analysis of ctDNA sequencing data 594 
FASTQ files were generated from the sequencer's output using Illumina 595 
bcl2fastq2 software (v.2.17.1.14, Illumina) with the default chastity filter to 596 
select sequence reads for subsequent analysis. All sequencing reads were 597 
aligned to the human genome reference sequence (GRCh37) using the BWA 598 
(v. 0.7.12) MEM algorithm. Picard tools (v.2.1.0) were used to mark/remove 599 
PCR duplicates and to calculate sequencing metrics. Somatic point mutations 600 
were called using both MuTect (v1) and also using the commercial software, 601 
Biomedical Genomics Workbench (BGW) v5.0 (Qiagen) by comparing plasma 602 
ctDNA to germline control DNA. Somatic InDels were called using both 603 
VarScan and Biomedical Genomics Workbench. Mutations called by two 604 
independent pipelines (MuTect+BGW or VarScan+BGW) were classed as 605 
high confidence and kept. Mutations within the 19 or 24-gene tumour panel 606 
were reported as low confidence if only called in a single pipeline. To ensure 607 
confidence in reported mutations a minimum of 10 variant reads at the 608 
reported loci and a 2.5% VAF threshold was applied to all ctDNA analysis. 609 
Functional annotation of somatic variants was performed using ANNOVAR, 610 
the resultant VCF was analysed through the Qiagen Clinical Insight (QCI) for 611 
Somatic Cancer platform (Qiagen) and reports were generated for discussion 612 
in the TARGET Molecular Tumour Board. ‘Actionable’ was defined as a target 613 
of known pathogenic significance for which either a licensed or experimental 614 
agent or relevant clinical trial was available at the time of discussion.  615 
 616 
CNA analysis of ctDNA  617 
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Standard low-pass WGS CNA analysis was performed on 8 patient samples 618 
as previously described (21) and analysed using HMM copy. CNA analysis of 619 
ctDNA hybridisation NGS data was performed using CNVkit software as 620 
previously described (27) and gene-level amplifications and deletions reported 621 
for the 641 cancer associated genes within the Agilent panel. For comparison 622 
to tumour CNA the gene list was restricted to the 315 genes reported by 623 
FoundationOne®. 624 
 625 
Analysis of Tumour DNA 626 
Between 1-3 5 µM thick sections from FFPET specimens were processed to 627 
extract genomic DNA using the Roche cobas® DNA Sample Preparation Kit. 628 
Tumour DNA was analysed using Sequenome OncoCarta panel v1.0 629 
following the manufacturer’s protocol or using the Qiagen Human Clinically 630 
Relevant Tumour GeneRead DNAseq Targeted Panel V2 as described. The 631 
OncoCarta™ v1.0 and Qiagen Clinically Relevant Tumour Targeted Panel V2 632 
assays were validated to detect mutations to a VAF of 10% and 4% 633 
respectively. Following PCR based target enrichment; GeneRead libraries 634 
were prepared using the Illumina TruSeq PCR Free indexes and reagents. All 635 
NGS libraries were pair-end sequenced on an Illumina MiSeq using v2 636 
sequencing chemistry (2x150cycles). Reads were aligned with BWA-MEM 637 
(version 0.6.2) hybrid to the human genome build GRCh37(hg19) followed by 638 
local realignment with ABRA (v0.96).  Variant calling used a custom 639 
bioinformatics analysis pipeline which was validated to detect low level 640 
mosaic calls down to 4% allele fraction and uses a software consensus 641 
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between VarScan v2.3.9 and DREEP v0.7. Large indel events are assessed 642 
using Pindel (v0.2.4.t).  643 
Variants identified bioinformatically were assessed for trueness and clinical 644 
relevance by two independent clinical scientists blinded to each other’s 645 
interpretation.   ACMG/ACGS & AMP guidelines on variant interpretation were 646 
followed in the assessment of pathogenicity and clinical relevance of variants. 647 
 648 
Statistics and Reproducibility 649 
The statistical methods used for each analysis are described within the figure 650 
legends and on the Life Science Reporting Summary associated with the 651 
manuscript. 652 
 653 
Development of eTARGET 654 
End-user and data requirements were defined based on the existing TARGET 655 
reports, exploration of data sources and interviews with the principal 656 
investigator and data controllers. After completion of a successful prototype, a 657 
beta version of eTARGET was developed in Microsoft Azure, a secure cloud-658 
computing platform. Components included a storage account for data upload, 659 
a database for storing and integrating the data and a web-application to view 660 
the data.  The web application, database and process server are backed up. 661 
Network traffic to resources is enforced and controlled by Network Security 662 
Group that contains a list of security rules. The data are stored within the 663 
European Economic Area (EEA) and all storage is encrypted.  664 
Access to eTARGET is restricted to members of the MTB who have an 665 
account defined in the Azure Active Directory (AAD) and within the application 666 
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itself.  Access to Azure File Upload Storage is restricted to users with an 667 
account in the AAD, which has been defined as a contributor to the storage 668 
account. 669 
 670 
Foundation Medicine FoundationOne® testing of tumour  671 
A subset of 51/100 TARGET patients had sufficient biopsy material for 672 
FoundationOne® testing to be performed on FFPE biopsies of tumour tissue. 673 
Of the 51 patients sent for testing 39 were successfully analysed with all 39 674 
having at least 1 variant reported and 23 having CNA events reported 675 
(Supplementary Table ST5). This data was used for comparison of variant 676 
and CNA calling from the ctDNA of the corresponding patients.  677 
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Data availability statement  678 
All the data generated or analysed during this study are included in this 679 
published article or are available from the corresponding author upon 680 
reasonable request. Genome data has been deposited at the European 681 
Genome-phenome Archive (EGA), which is hosted at the EBI and the CRG, 682 
under accession number EGAS00001003407. 683 
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